Cefilavancin

DB05735InvestigationalSmall molecule

Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.

Mechanism: Pharmacologically active on Penicillin-binding protein
Curator reviewed
Primary indication: Investigated for use/treatment in bacterial infection, skin infections/disorders, and staph bacterial infections.Curator reviewed
Formula / weight: C₈₇H₉₅Cl₃N₁₆O₂₈S₂ · 1983.27 g/mol (avg)
Code names: TD-1792

Resolves to

Compound

UNIIF76229E21MCAS722454-12-8ChEMBLCHEMBL4297645

Structure

InChIKeyOGUAFUAJSPORAH-KHCCTVBNSA-NSMILES

[H][C@]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCCCNC(=O)[C@H]1NC(=O)[C@H]2NC(=O)[C@H](NC(=O)[C@@H]3NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C4=CC=C(OC5=C(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@]6([H])O[C@H]6C[C@](C)(N)[C@H](O)[C@H](C)O6)C(OC6=C(Cl)C=C(C=C6)[C@H]2O)=CC3=C5)C(Cl)=C4)C2=CC(=C(O)C=C2)C2=C1C=C(O)C=C2O)\C1=C(Cl)SC(N)=N1)C([O-])=O

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Cefilavancin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account